Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tozuleristide - Blaze Bioscience

Drug Profile

Tozuleristide - Blaze Bioscience

Alternative Names: BLZ-100; Chlorotoxin conjugated to indocyanine green dye - Blaze Bioscience; Chlorotoxin-indocyanine-green-conjugate; CyTP-007; Tumor Paint BLZ-100; Tumour paint

Latest Information Update: 15 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blaze Bioscience
  • Developer Blaze Bioscience; Seattle Children's Hospital
  • Class Biological toxins; Drug conjugates; Imaging agents; Indoles; Peptides
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III CNS cancer
  • Phase I Breast cancer; Glioma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 10 May 2019 Efficacy and adverse events data from a phase I trial in Glioma (Diagnosis) released by Blaze Bioscience
  • 26 Nov 2018 Phase-II/III clinical trials in CNS cancer (Diagnosis, In infants, In children, In adolescents, In adults) in USA (IV) (NCT03579602)
  • 06 Jul 2018 Blaze Bioscience plans a phase II/III trial for CNS cancer (Diagnosis, In children, In infants, In adolescents, In adults) in Unknown country (IV), in August 2018 , (NCT03579602)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top